All News

Found 95 articles

• 

  FDA Action Alert: Incyte, Verrica and Ascendis

  9/20/2021

  From time to time, the U.S. FDA requests additional data from companies who have submitted an application for a new drug or biologic. What’s a bit unusual is every single PDUFA date this week had that happen.

• Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

  9/20/2021

  Verrica Pharmaceuticals Inc. (the “Company”) (Nasdaq: VRCA), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum)

• Common Warts Therapeutics Market: Prescription Medications & Cryotherapy to Lead the Global Market

  8/18/2021

  Common warts, or cutaneous warts, are abnormal epithelial growth in the skin and mucous membrane. Common warts are known to be caused by the Human Papilloma Virus (HPV).

• Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

  8/10/2021

  Verrica Pharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2021.

• Candel Therapeutics Appoints Diem Nguyen, Ph.D., M.B.A., to Its Board of Directors

  7/15/2021

  Candel Therapeutics, Inc. today announced it has appointed Diem Nguyen, Ph.D., M.B.A., to its Board of Directors.

• Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

  7/9/2021

  Verrica Pharmaceuticals Inc. today announced the appointment of Terry Kohler as Chief Financial Officer.

• Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

  5/28/2021

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for VP-102

• Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference

  5/26/2021

  Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that Ted White, Verrica President and CEO, will present a business overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 2:00 p.m. ET.

• Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

  5/12/2021

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

• Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

  5/7/2021

  – Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised approximately $30 million, before offering expenses, in an underwritten public offering – – Granted Torii Pharmaceutical Co., Ltd. an exclusive license to develop and commercialize VP-102 for molluscum and common warts in Japan; Company recognized license revenues of $12.0 million in the first quarter –

• Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

  4/6/2021

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 8:45 a.m. ET.

• Warts Therapeutics Market: Recurrence of Warts to Drive the market

  4/5/2021

  TMR’s report on the global warts therapeutics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030.

• Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association

  3/29/2021

  Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Gary Goldenberg, M.D., Verrica’s Chief Medical Officer, has been elected as an active member into the American Dermatological Association (ADA).

• Verrica Announces Pricing of Public Offering of Common Stock - Mar 23, 2021

  3/23/2021

  Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced the pricing of its underwritten public offering of 2,033,899 shares of its common stock at a price to the public of $14.75 per share.

• Verrica Announces Proposed Public Offering of Common Stock

  3/22/2021

  Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

• Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts

  3/17/2021

  Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced today that it has entered into a License Agreement with Torii Pharmaceutical Co., Ltd.

• Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

  3/4/2021

  Verrica Announces Torii Pharmaceutical Has Exercised Option to Acquire Exclusive License Agreement to Develop and Commercialize VP-102 in Japan Triggering 60-Day Period to Finalize and Execute License Agreement

• Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

  3/3/2021

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place March 9-10, 2021. .

• Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference

  2/23/2021

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Cowen 41 st Annual Health Care Conference on Tuesday, March 2, 2021, at 11:50 a.m. ET.

• Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

  2/17/2021

  - PDUFA goal date assigned is June 23, 2021 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children -